-

Xcellerant Ventures Invests in Mindset Medical to Advance Contactless Vital Sign Monitoring

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Xcellerant Ventures (XVC) is proud to announce its investment in Mindset Medical (Mindset), a Phoenix-based digital health company pioneering software-only, contactless vital sign monitoring. This investment marks the latest addition to Xcellerant VC Fund 1, underscoring the fund's commitment to backing transformative healthcare technologies. John Shufeldt, Managing Partner at XVC, will join the board.

Mindset's proprietary remote photoplethysmography (rPPG) technology transforms smartphones, tablets, or laptops into contactless vital sign measurement tools. Unlike hardware-dependent wearables, Mindset's software platform enables patients to record their vital signs using cameras on devices they already own. Tracking pulse rate, respiratory rate, and blood pressure empowers patients to manage their own health and may reduce the risk of chronic diseases or medical conditions.

Recently, the company secured its second FDA 510(k) clearance in under a year. With clearance for pulse and respiratory rate, doctors can seamlessly monitor their patients' vital signs in hospitals, clinics, long-term care facilities, and in patients' homes.

"We are excited to support Mindset Medical as they redefine remote patient monitoring with scalable, clinically validated software," said John Shufeldt. "Their regulatory momentum and proven leadership position them to lead in contactless health monitoring."

Mindset will utilize the new funding to accelerate the development of blood pressure monitoring for clinician use, expand commercialization efforts, and strengthen partnerships with telehealth providers, health systems, and payers.

"We view Xcellerant Ventures as more than a capital partner—their deep expertise in healthcare, digital health, and scaling clinical technologies makes them an ideal ally as we accelerate commercialization," said Mitch Foster, CEO of Mindset, "Their track record of guiding early-stage healthtech companies through regulatory pathways, strategic partnerships, and payer/provider adoption gives us confidence they will add immense strategic value alongside our growth."

About Xcellerant Ventures

Phoenix-based XVC is a venture capital firm investing in early and seed stage startups within the HealthTech, MedTech, and BioTech sectors. The firm focuses on identifying and supporting transformational trends driving healthcare innovation.

About Mindset Medical

Mindset delivers a software-only, camera-based vital sign monitoring platform for patients and physicians. Their solutions reduce clinical friction, protect user privacy with on-device processing, and integrate seamlessly into healthcare workflows via APIs. The company is building a scalable pipeline of contactless monitoring solutions to set the next standard in remote patient care.

Contacts

Xcellerant Ventures
Tiffany Youtchoko
tyoutchoko@xcellerantventures.com

Mindset Medical
info@mindsetmedical.com
sales@mindsetmedical.com

More News From Xcellerant Ventures

$7 Million Investment Fuels Health Tech Innovation in Arizona

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Xcellerant Ventures (XVC) is proud to announce a strategic partnership with AZ Venture Capital Inc. (AVC), bringing $7 million in new funding to Arizona-based health technology startups. The $7 million, total, that is available for Arizona startups was made possible by a $5 million investment by AVC into XVC’s Fund. According to Douglas Sylvester, a general partner in XVC, “The $5 million from AZ Venture Capital spurred our investors to add $2 million to our...

Xcellerant Ventures Leads DeepLook Medical’s Series A Round

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Xcellerant Ventures is proud to announce that it will lead DeepLook Medical’s Series A funding round. DeepLook Medical, a healthtech company specializing in visual enhancement technology for advanced medical imaging, marks the 11th investment in Xcellerant VC Fund 1. Michael Shufeldt, MBA, Principal at Xcellerant Ventures, will join the board. DeepLook Medical's flagship product, DL Precise™, is an innovative AI-powered software that equips healthcare profess...

Xcellerant Ventures Ends First Year with 10th Investment, Leading CRISPR QC’s $10 Million Series A Round

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Xcellerant Ventures is proud to announce its investment in CRISPR QC, the San Diego-based biotechnology company that has developed the world’s first platform to precisely analyze the quality of the CRISPR/CAS9 gene editing system. By providing a way to standardize measurements for efficiency and accuracy, CRISPR QC enables pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next generation personalized medicine...
Back to Newsroom